MaxCyte to Acquire Akron Bio to Drive Revenue Growth and Profitability
MaxCyte (MXCT) has entered into a definitive agreement to acquire Akron Bio from Arcline Investment Management following a competitive bidding process. The acquisition is a strategic move intended to accelerate the company's path toward profitability by expanding its technological capabilities and market reach. The deal is expected to significantly bolster MaxCyte's financial outlook, with management projecting that Akron Bio will contribute approximately $28 million in revenue for the 2026 fiscal year. This acquisition positions MaxCyte to achieve a total projected revenue of at least $34.5 million by 2026.
Tickers: $MXCT